arrow
M

Maud Kamal

irccs policlinico gemelli
H指数:38
被引数:6,197

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Integrative genomic and transcriptomic profiles from a prospective cervical cancer study

前瞻性宫颈癌研究中整合的基因组与转录组特征

2026-07-220
OA
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis

SAFIR02-Lung队列中肺腺癌的分子分析揭示了新的与转移相关的染色体拷贝数改变,包括频繁的突变特异性KRAS等位基因失衡,并将CDKN2A纯合子缺失鉴定为不良预后的独立生物标志物。

2025-09-110
PRE
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial

帕博利珠单抗和伏立诺他联合治疗复发性/转移性鳞状细胞癌的疗效:一项II期篮式试验

2025-06-300
OAAI
Deciphering molecular relapse and intra-tumor heterogeneity in non-metastatic resectable head and neck squamous cell carcinoma using circulating tumor DNA
2025-01-010
PRE
The genomic and transcriptomic landscape of metastastic urothelial cancer (vol 15, 8603, 2024)

《转移性尿路上皮癌的基因组与转录组景观》(vol 15, 8603, 2024)

2024-10-300
OA
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors
2024-08-020
OA
Metastatic renal cell carcinoma with occult primary: a multicenter prospective cohort
2024-07-180
OAAI
Biomarkers of response and progression to Pembrolizumab and Vorinostat combination in late-stage squamous cell carcinoma patients of different locations included in the PEVOsq basket trial
2024-03-220
PRE
Circulating HPV DNA as a potential biomarker to monitor response to the pembrolizumab and vorinostat combination in patients with squamous cell carcinoma of different locations
2024-03-220
PRE
Multiregion spatial sequencing of early- stage head and neck squamous cell carcinoma revealed theranostic intratumor heterogeneity
2024-03-220
PRE
Metastatic renal cell carcinoma with occult primary: Clinical and biological evidence for a new entity of cancers of unknown primary that beneficiates from tissue-tailored treatment
2024-03-220
PRE
Genomic alterations predictive of outcome in early staged cervical cancer: A translational investigation from the SENTICOL III trial
2024-03-220
PRE
National multidisciplinary tumor board improves diagnostic stratification and therapeutic management in cancers of unknown primary
2024-03-220
PRE
Integrative genomic and transcriptomic profiles from a prospective cervical cancer study (RAIDs)
2024-03-220
PRE
Single-cell and spatial dissection of the effect of combined PD-L1 and TGFb blockade by bintrafusp alfa from the ICING window-of-opportunity trial in resectable locally advanced HNSCC patients
2024-03-220
PRE